Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

I-Mab to Start China Phase II Trial of Immunotherapy for GBM

publication date: May 21, 2020

I-Mab, a Shanghai biopharma, announced approval to start a China Phase II trial of a novel long-acting recombinant human interleukin-7 (rhIL-7) in lymphopenic patients with glioblastoma multiforme (GBM). In late 2017, I-Mab in-licensed China rights to TJ107/HyLeukin-7™ (efineptakin alfa) from Korea's Genexine in a deal worth up to $548 million. An immunotherapy, HyLeukin is based on interleukin-7, a factor in the proliferation and homeostasis of T cells. More details....

Stock Symbols: (NSDQ: IMAB) (KOSDAQ: 095700)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020